The group at Memorial Sloan Kettering Cancer Center reported the occurrence of CD19-negative relapses in 14% of adult B-ALL patients treated with CART19 (CD28 costimulation). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.